Research Papers

14 of 2264 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Targeted nanoprobes reveal early time point kinetics in vivo by time-resolved MRI.
Bhirde A; Guo N; Chen X.
Theranostics (Unknown)
Published: 2011
2/6 Transparent
Funding Declared
Investigation of In Vivo Targeting Kinetics of α(v)β(3)-Specific Superparamagnetic Nanoprobes by Time-Resolved MRI.
Kessinger CW; Togao O; Khemtong C; Huang G; Takahashi M; Gao J.
Theranostics (Unknown)
Published: 2011
2/6 Transparent
Funding Declared
Folic Acid-conjugated Graphene Oxide loaded with Photosensitizers for Targeting Photodynamic Therapy.
Huang P; Xu C; Lin J; Wang C; Wang X; Zhang C; Zhou X; Guo S; Cui D.
Theranostics (Unknown)
Published: 2011
2/6 Transparent
Funding Declared
Photosensitizer-conjugated human serum albumin nanoparticles for effective photodynamic therapy.
Jeong H; Huh M; Lee SJ; Koo H; Kwon IC; Jeong SY; Kim K.
Theranostics (Unknown)
Published: 2011
2/6 Transparent
Funding Declared
Multimodality Imaging of Integrin α(v)β(3) Expression.
Zhang Y; Yang Y; Cai W.
Theranostics (Unknown)
Published: 2011
2/6 Transparent
Funding Declared
Application of molecular ultrasound for imaging integrin expression.
Kiessling F; Gaetjens J; Palmowski M.
Theranostics (Unknown)
Published: 2011
1/6 Transparent
Radiolabeled Cyclic RGD Peptides as Radiotracers for Imaging Tumors and Thrombosis by SPECT.
Zhou Y; Chakraborty S; Liu S.
Theranostics (Unknown)
Published: 2011
2/6 Transparent
Funding Declared
PET Imaging of Integrin αVβ3 Expression.
Beer AJ; Kessler H; Wester HJ; Schwaiger M.
Theranostics (Unknown)
Published: 2011
1/6 Transparent
Tunable plasmonic nanoprobes for theranostics of prostate cancer.
Lukianova-Hleb EY; Oginsky AO; Samaniego AP; Shenefelt DL; Wagner DS; Hafner JH; Farach-Carson MC; Lapotko DO.
Theranostics (Unknown)
Published: 2011
2/6 Transparent
Funding Declared
Introducing Theranostics Journal - From the Editor-in-Chief.
Chen XS.
Theranostics (Unknown)
Published: 2011
PET imaging of CXCR4 using copper-64 labeled peptide antagonist.
Jacobson O; Weiss ID; Szajek LP; Niu G; Ma Y; Kiesewetter DO; Farber JM; Chen X.
Theranostics (Unknown)
Published: 2011
2/6 Transparent
Funding Declared
Why integrin as a primary target for imaging and therapy.
Niu G; Chen X.
Theranostics (Unknown)
Published: 2011
2/6 Transparent
Funding Declared
F-Labeled GRPR Agonists and Antagonists: A Comparative Study in Prostate Cancer Imaging.
Yang M; Gao H; Zhou Y; Ma Y; Quan Q; Lang L; Chen K; Niu G; Yan Y; Chen X.
Theranostics (Unknown)
Published: 2011
2/6 Transparent
Funding Declared
Real-time video imaging of protease expression in vivo.
Zhu L; Xie J; Swierczewska M; Zhang F; Quan Q; Ma Y; Fang X; Kim K; Lee S; Chen X.
Theranostics (Unknown)
Published: 2011
2/6 Transparent
Funding Declared